D-ribose aids advanced ischemic heart failure patients.
Int J Cardiol. 2009 Sep 11;137(1):79-80.
MacCarter D, Vijay N, Washam M, Shecterle L, Sierminski H, St Cyr JA.
Patients with advanced heart failure are exercise intolerant. Low cellular energy levels in the failing heart have been proposed. Energy enhancing substrates have revealed mixed results. Ribose, a pentose monosaccharide, has shown to replenish low myocardial energy levels, improving cardiac dysfunction following ischemia, and improving ventilation efficiency in patients with heart failure. As current pharmaceuticals do not address cellular energy levels, this study was designed to investigate the role of ribose on ventilation at anaerobic threshold in congestive heart failure patients. d-ribose (5 gms/dose, tid) was assessed in 16 NYHA class III-IV, heart failure patients with VO(2), tidal volume/VCO(2), heart rate/tidal volume evaluated at 8 weeks. All patients had a significant improvement in ventilatory parameters at anaerobic threshold, along with a 44% Weber class improvement. Ribose improved the ventilatory exercise status in advanced heart failure patients.
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.
J Altern Complement Med. 2006 Nov;12(9):857-62.
Teitelbaum JE, Johnson C, St Cyr J.
OBJECTIVES: Fibromyalgia (FMS) and chronic fatigue syndrome (CFS) are debilitating syndromes that are often associated with impaired cellular energy metabolism. As D-ribose has been shown to increase cellular energy synthesis in heart and skeletal muscle, this open-label uncontrolled pilot study was done to evaluate if D-ribose could improve symptoms in fibromyalgia and/or chronic fatigue syndrome patients.
DESIGN: Forty-one (41) patients with a diagnosis of FMS and/or CFS were given D-ribose, a naturally occurring pentose carbohydrate, at a dose of 5 g t.i.d. for a total of 280 g. All patients completed questionnaires containing discrete visual analog scales and a global assessment pre- and post-D-ribose administration.
RESULTS: D-ribose, which was well-tolerated, resulted in a significant improvement in all five visual analog scale (VAS) categories: energy; sleep; mental clarity; pain intensity; and well-being, as well as an improvement in patients’ global assessment. Approximately 66% of patients experienced significant improvement while on D-ribose, with an average increase in energy on the VAS of 45% and an average improvement in overall well-being of 30% (p < 0.0001).
CONCLUSIONS: D-ribose significantly reduced clinical symptoms in patients suffering from fibromyalgia and chronic fatigue syndrome.
Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study.
European Journal of Heart Failure. 2003;5(5): 615-619.
Heyder Omran, Stefan Illiena, Dean MacCarterb, John St. Cyrb and Berndt Lüderitz.
Patients with chronic coronary heart disease often suffer from congestive heart failure (CHF) despite multiple drug therapies. -Ribose has been shown in animal models to improve cardiac energy metabolism and function following ischaemia. This was a prospective, double blind, randomized, crossover design study, to assess the effect of oral -ribose supplementation on cardiac hemodynamics and quality of life in 15 patients with chronic coronary artery disease and CHF. The study consisted of two treatment periods of 3 weeks, during which either oral -ribose or placebo was administered followed by a 1-week wash out period, and then administration of the other supplement. Assessment of myocardial functional parameters by echocardiography, quality of life using the SF-36 questionnaire and functional capacity using cycle ergometer testing was performed. The administration of -ribose resulted in an enhancement of atrial contribution to left ventricular filling (40±11 vs. 45±9%, P=0.02), a smaller left atrial dimension (54±20 vs. 47±18 ml, P=0.02) and a shortened E wave deceleration (235±64 vs. 196±42, P=0.002) by echocardiography. Further, -ribose also demonstrated a significant improvement of the patient’s quality of life (417±118 vs. 467±128, P0.01). In comparison, placebo did not result in any significant echocardiographic changes or in quality of life. This feasibility study in patients with coronary artery disease in CHF revealed the beneficial effects of -ribose by improving diastolic functional parameters and enhancing quality of life.
The Effects of Four Weeks of Ribose Supplementation on Body Composition and Exercise Performance in Healthy, Young, Male Recreational Bodybuilders: A Double-Blind, Placebo-Controlled Trial.
Current Therapeutic Research 2002;63(8):486-495 .
Van Gammeren D, Falk D and Antonio J.
BACKGROUND: Ribose is a pentose sugar that is present in ribonucleic acids, riboflavin, nucleotides, and adenosine triphosphate. Whether exogenous ribose administration affects skeletal muscle concentrations of total adenine nucleotides is unknown. Whether supplementation with ribose positively affects body composition or exercise performance in recreational bodybuilders also is unknown.
OBJECTIVE: The purpose of this double-blind, placebo-controlled trial was to determine the effects of 4 weeks of ribose supplementation on body composition and exercise performance in healthy, young, male recreational bodybuilders.
METHODS: Healthy, male recreational bodybuilders aged 18 to 35 years were recruited and randomized to a ribose-supplemented group (10 g/d in powder formulation) or a placebo group (dextrose). Each subject participated in a heavy-resistance training program designed to increase skeletal muscle mass. Body composition (ie, body weight, body fat, lean body mass, fat mass, and bone mineral content) was assessed using dual-energy x-ray absorptiometry analysis. Muscular strength (as measured by a l-repetition maximum-strength [ l-RM] bench press) and total work performed (as measured by total repetitions for 10 sets of bench presses before muscular failure; l-minute resting interval between sets) to muscular failure at a submaximal load (100% of pretest body weight) were ascertained. In addition, 24-hour dietary recalls were obtained before and after the study.
RESULTS: Twenty men (mean age SE, 23.9 1.4 years) were enrolled; 19 subjects completed 24hour dietary recalls and exercise performance testing; 12 subjects completed the study (24-hour dietary recalls, exercise performance, and body composition). No baseline differences were found between the 2 groups for any of the measured parameters. The ribose supplemented group experienced a significant pretreatment-to-posttreatment increase in the total work performed, whereas the placebo group did not change significantly (24.5 f 7.6 to 29.3 f 7.5 repetitions; 19.6% ribose [P = 0.0281 vs 34.1 f 8.6 to 38.2 f 8.0 repetitions, 12.0% placebo). In addition, the ribosesupplemented group expe rienced a significant increase in I-RM bench press strength, whereas the placebo group did not change significantly (114.1 f 13.6 to 117.7 f 14.0 kg, 3.2% ribose [P = O.OOS] vs 129.6 f 14.2 to 131.8 14.5 kg, 1.7% placebo). No pretreatmentto- posttreatment within-group or between-group differences were found for any of the measures of body composition or the 24-hour dietary data.
CONCLUSION: The results of this study indicate that supplementation with ribose 10 g/d for 4 weeks resulted in significant increases in muscular strength and total work performed in recreational bodybuilders in this study, although no significant changes in body composition or 24hour dietary data were found.